Analysts Offer Insights on Healthcare Companies: DaVita (DVA) and Immunocore Holdings (IMCR)
TipRanks (Wed, 4-Feb 6:40 AM ET)
Balanced View: DaVita’s near-term EBIT upside offset by structural growth hurdles
TipRanks (Tue, 3-Feb 8:26 PM ET)
Analysts Offer Insights on Healthcare Companies: InnovAge Holding (INNV) and DaVita (DVA)
TipRanks (Tue, 3-Feb 8:21 PM ET)
DaVita Earnings Call Signals Cautious Optimism
TipRanks (Tue, 3-Feb 7:25 PM ET)
DaVita Stock (DVA) Soars 20% as Financial Results Beat Wall Street Estimates
TipRanks (Tue, 3-Feb 2:11 PM ET)
DaVita’s Strategic Investment in Elara Caring Aims to Transform Home-Based Kidney Care
Market Chameleon (Tue, 3-Feb 5:28 AM ET)
Analysts Conflicted on These Healthcare Names: CareDx (CDNA) and DaVita (DVA)
TipRanks (Tue, 3-Feb 9:40 AM ET)
TipRanks (Tue, 3-Feb 8:51 AM ET)
DaVita’s 2025 Results Highlight Strong Adjusted Earnings Amid Share Buybacks and Margin Stability
Market Chameleon (Tue, 3-Feb 2:09 AM ET)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and DaVita (DVA)
TipRanks (Tue, 3-Feb 2:30 AM ET)
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Davita trades on the NYSE stock market under the symbol DVA.
As of February 5, 2026, DVA stock price climbed to $149.22 with 2,067,145 million shares trading.
DVA has a beta of 0.30, meaning it tends to be less sensitive to market movements. DVA has a correlation of 0.03 to the broad based SPY ETF.
DVA has a market cap of $9.98 billion. This is considered a Mid Cap stock.
Last quarter Davita reported $4 billion in Revenue and $3.40 earnings per share. This beat revenue expectation by $104 million and exceeded earnings estimates by $.19.
In the last 3 years, DVA traded as high as $179.60 and as low as $71.51.
The top ETF exchange traded funds that DVA belongs to (by Net Assets): RSP, VTI, VOO, VB, IVV.
DVA has underperformed the market in the last year with a return of -15.9%, while SPY returned +13.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DVA shares. However, DVA has outperformed the market in the last 3 month and 2 week periods, returning +24.4% and +40.4%, while SPY returned +0.6% and -1.1%, respectively. This indicates DVA has been having a stronger performance recently.
DVA support price is $139.00 and resistance is $145.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DVA shares will trade within this expected range on the day.